Emerging drugs for the treatment of hepatocellular carcinoma
INTRODUCTION: Hepatocellular carcinoma (HCC) remains a leading cause of liver-related mortality. Cirrhosis of any etiology is the major risk factor although HCC can develop in its absence in patients with hepatitis B and increasingly in those with nonalcoholic fatty liver disease. When detected at an early stage, curative options include surgical resection, liver transplantation, and/or ablative therapies. Unfortunately, most cases of HCC are recognized at an advanced stage when options are limited and noncurative. However, new systemic therapies with tyrosine kinase inhibitors and immunotherapy have expanded therapeutic options in advanced HCC. Advances in systemic therapy have given patients with advanced HCC hope and prolonged their survival.
AREAS COVERED: We discuss recent data and ongoing research efforts to improve the treatment of hepatocellular carcinoma with discussion of current and upcoming systemic therapies combining agents of different classes.
EXPERT OPINION: Systemic therapy for HCC is in evolution. The inclusion of immunotherapy to systemic therapy has revolutionized the field of HCC treatment. Identification of the appropriate combination and sequence of systemic therapy coupled with discovery of reliable HCC biomarkers will lead to improved survival and individualized HCC therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 27(2022), 2 vom: 01. Juni, Seite 141-149 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ayoub, Walid S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.08.2022 Date Revised 30.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2022.2083107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341646628 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341646628 | ||
| 003 | DE-627 | ||
| 005 | 20231226012249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2022.2083107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341646628 | ||
| 035 | |a (NLM)35642526 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ayoub, Walid S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging drugs for the treatment of hepatocellular carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2022 | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Hepatocellular carcinoma (HCC) remains a leading cause of liver-related mortality. Cirrhosis of any etiology is the major risk factor although HCC can develop in its absence in patients with hepatitis B and increasingly in those with nonalcoholic fatty liver disease. When detected at an early stage, curative options include surgical resection, liver transplantation, and/or ablative therapies. Unfortunately, most cases of HCC are recognized at an advanced stage when options are limited and noncurative. However, new systemic therapies with tyrosine kinase inhibitors and immunotherapy have expanded therapeutic options in advanced HCC. Advances in systemic therapy have given patients with advanced HCC hope and prolonged their survival | ||
| 520 | |a AREAS COVERED: We discuss recent data and ongoing research efforts to improve the treatment of hepatocellular carcinoma with discussion of current and upcoming systemic therapies combining agents of different classes | ||
| 520 | |a EXPERT OPINION: Systemic therapy for HCC is in evolution. The inclusion of immunotherapy to systemic therapy has revolutionized the field of HCC treatment. Identification of the appropriate combination and sequence of systemic therapy coupled with discovery of reliable HCC biomarkers will lead to improved survival and individualized HCC therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atezolizumab | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a cabozantinib | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a lenvatinib | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a ramucirumab | |
| 650 | 4 | |a regorafenib | |
| 650 | 4 | |a sorafenib | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Jones, Patricia D |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ju Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 27(2022), 2 vom: 01. Juni, Seite 141-149 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:2 |g day:01 |g month:06 |g pages:141-149 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2022.2083107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 2 |b 01 |c 06 |h 141-149 | ||